

binx health raises \$104 million in Series E financing led by Orbimed Advisors

Torreya Capital served as exclusive placement agent on this transaction

Boston, MA, June 2, 2021

binx health ("the Company"), a healthcare technology and diagnostics company that provides convenient point-of-care and at-home diagnostic testing for sexually transmitted diseases, announced the closing of a Series E financing for \$104 million. The financing was led by OrbiMed, and included other new investors Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global, along with existing investors Life Science Partners and Johnson and Johnson Development Corporation, among others. In connection with the financing, Andrew Goldman, Co-founder and Managing Partner of Hildred Capital Management, will join the Company's Board of Directors.

The Company plans to use these proceeds to support the expansion of manufacturing for first-of-kind, FDA-cleared, CLIA-waived binx io rapid molecular diagnostic test, menu expansion, and the company's data and software architecture for its at-home and in-clinic businesses. For in-clinic/at-retail locations, the binx io rapid molecular point of care platform offers onsite convenience in a CLIA-waived solution for chlamydia and gonorrhea that can provide testing, diagnosis and treatment in the same visit. For those unable to access in-person testing, binx at-home offers access to testing through remote sample collection. Through this omnichannel platform, the Company facilitates enterprise customers to access and service more patient populations, despite location collection preference.

Torreya advised binx health on the transaction, which highlights Torreya's strength in advising companies in the pharma services sector and demonstrates our deep relationships within the private equity community. Torreya has raised over \$600mm in capital for its clients in the past 12 months.

ABOUT BINX HEALTH:

For more information about binx, please see: www.mybinxhealth.com

Deal Press Release

Torreya Contacts

TOM BABICH

Head of Capital Markets | New York Office
tom.babich@torreya.com | 212.257.5811 | [BIO](#)

BRETT POPE

Managing Director | Dallas
brett.pope@torreya.com | 646.789.2201 | [BIO](#)



Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.